Asset Details
Do you wish to reserve the book?
Physical Health Monitoring for Metabolic Syndrome in Patients Prescribed Olanzapine in Oman
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Physical Health Monitoring for Metabolic Syndrome in Patients Prescribed Olanzapine in Oman
Do you wish to request the book?
Physical Health Monitoring for Metabolic Syndrome in Patients Prescribed Olanzapine in Oman
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Physical Health Monitoring for Metabolic Syndrome in Patients Prescribed Olanzapine in Oman
2017
Overview
Background: Clozapine and olanzapine are highly associated with the risk of metabolic syndrome resulting in lower functional outcomes, poorer quality of life and non-compliance to treatment. Objective: The current study examined the rate of assessment of metabolic syndrome parameters in patients on olanzapine attending Almasarrah Hospital in Muscat. Methods: Patients starting olanzapine between January 2014 and May 2015 were recruited to the study, which is based on the retrospective revision of cases gathered from medical records over a period of 18 months. Patients aged 18 years or above, who were prescribed olanzapine and had five or more hospital visits were included. Demographics included physical health parameters with regards to metabolic syndrome, namely blood pressure, weight, fasting blood sugar level and lipid profile. Results were compared to the ADA-APA monitoring protocol for patients on second generation antipsychotics. Results: N=46 patients met study inclusion criteria. No gender difference was identified. Most (74%) were between 21 and 40 years of age with 50% diagnosed with schizophrenia; 50% did not have a baseline lipid profile and 30% had blood sugar levels checked prior to olanzapine therapy. The majority (97%) had blood pressure and weight measured at baseline and follow-up. Overall, none of the patients matched the full standards of the ADA-APA protocol. Conclusion: Screening for metabolic syndrome among patient prescribed olanzapine in Almasarrah Hospital is behind international standards. This is especially true for lipid profile and fasting blood sugar level parameters. Findings are consistent with similar studies. Further studies should assess factors contributing to suboptimal monitoring of olanzapine-induced metabolic syndrome.
Publisher
اتحاد الاطباء النفسانيين العرب,Arab Federation of Psychiatry
We currently cannot retrieve any items related to this title. Kindly check back at a later time.